Ceregene, Inc.
Ceregene is developing gene therapies for a variety of central nervous system disorders. Its pipeline includes two leading candidates in clinical trials: CERE-120 is being investigated for treatment of Parkinson's disease while CERE-110 is being tested on Alzheimer's disease. Both candidates are based upon Ceregene's technology that delivers neurotrophic factors directly into dying neuron cells. The neurotrophic factors are then able to delay the progression of neurodegenerative diseases. Two other candidates are being developed to treat ALS and certain ocular diseases. Genzyme has joined into a partnership to develop and commercialize CERE-120. Additional funding has come from the Michael J. Fox Foundation.
Contact Details
Office Address
Ceregene, Inc.
9381 Judicial Dr., Ste. 130
San Diego, CA, USA 92121
Phone: (858) 458-8800
Fax: (858) 458-8801
Executives
Chairman
Stephen A. (Steve) Sherwin
President, CEO, and Director
Jeffrey M. Ostrove